Top stories in endocrinology: FDA grants breakthrough device designation for closed-loop insulin pump, approves mobile app to enhance insulin management

Among the top stories in endocrinology last week were the FDA granting breakthrough device designation for a personalized, closed-loop insulin pump and approving a mobile app designed to titrate individualized insulin doses for people with type 2 diabetes.

Other highlights included a study that determined adolescents with severe obesity who underwent bariatric surgery experienced a 25% reduction in resting energy expenditure 12 months after the procedure, a study that found adults with thyroid-stimulating hormone-secreting pituitary adenomas have a greater chance of biochemical remission after undergoing adjuvant treatment and findings that suggested bright sunlight exposure may decrease the risk for type 2 diabetes and CVD.

FDA grants breakthrough device designation for personalized, closed-loop insulin pump

The FDA on Tuesday granted breakthrough device designation for a personalized, closed-loop insulin pump system that is currently in development, according to a press release from Medtronic. Read more.

FDA approves mobile app to enhance insulin management in type 2 diabetes

The FDA on Wednesday granted 501(k) clearance for the first mobile app designed to titrate individualized insulin doses for people with type 2 diabetes, according to a press release from Hygieia. Read more.

Metabolic adaptation influences weight regain after bariatric surgery in teenagers

Adolescents with severe obesity who underwent bariatric surgery experienced a 25% reduction in resting energy expenditure 12 months after the procedure, a figure greater than the level predicted by current BMI, suggesting careful nutritional management is warranted. Read more.

Adjuvant therapy improves odds of thyroid-stimulating hormone-secreting pituitary adenoma remission

Adults with thyroid-stimulating hormone-secreting pituitary adenomas have a greater chance of biochemical remission after undergoing adjuvant treatment compared with neoadjuvant therapies, according to findings published in Pituitary. Read more.

Bright sunlight exposure may decrease risk for type 2 diabetes, CVD

Healthy, middle-aged adults exposed to more bright sunlight in the 7 days before providing a blood sample had lower levels of markers indicating risk for insulin resistance and dyslipidemia vs. adults exposed to less sunlight, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.